Search results for: grade
#33249773 2020/11/29 To Up
Does the definition of chronic active T-cell mediated rejection need revisiting?Similar to what is observed in native kidneys, tubulo-interstitial inflammation in scarred areas (i-IFTA) is commonly found in kidney allografts, and here independently associated with impaired outcome. Along with the observation that i-IFTA is preceded by acute T cell mediated rejection (TCMR) and/or suboptimal immunosuppression in a subset of cases, these data formed the basis for the introduction of the category of tubulointerstitial (grade I) chronic active TCMR (CA-TCMR) in the 2017 Banff classification.
Maarten Naesens, Mark Haas, Alexandre Loupy, Candice Roufosse, Michael Mengel
1187 related Products with: Does the definition of chronic active T-cell mediated rejection need revisiting?5 x 50 ug50 ug96T25 ml.10ml5x5 ml100ug100 tests100 plates100ug Lyophilized
#33249761 2020/11/29 To Up
Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.A previous Phase I/II study demonstrated that TAS-102 (trifluridine/tipiracil [FTD/TPI]) plus bevacizumab (Bev) has encouraging efficacy and controllable safety for patients with previously treated metastatic colorectal cancer. Therefore, we designed for assessing the efficacy and safety of FTD/TPI plus Bev in elderly patients with previously untreated metastatic colorectal cancer.
Eiji Oki, Akitaka Makiyama, Yuji Miyamoto, Masahiko Kotaka, Hirofumi Kawanaka, Keisuke Miwa, Akira Kabashima, Tomohiro Noguchi, Kotaro Yuge, Tomomi Kashiwada, Koji Ando, Mototsugu Shimokawa, Hiroshi Saeki, Yoshito Akagi, Hideo Baba, Yoshihiko Maehara, Masaki Mori
2555 related Products with: Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.100 plates1 ST100 tests1,000 tests
#33249738 2020/11/29 To Up
Changes in the UK renal oncologic surgical practice from 2008 to 2017: implications on cancer service provision and surgical training.To determine and analyse the temporal changes in oncologic nephrectomy practice and training opportunities using data obtained from the UK BAUS nephrectomy register from 2008 to 2017.
Conor M Devlin, Sarah Fowler, Chandra Shekhar Biyani, James A Forster
2278 related Products with: Changes in the UK renal oncologic surgical practice from 2008 to 2017: implications on cancer service provision and surgical training.100
No related Items
Error loading info... Pleas try again later.
#33249535 2020/11/28 To Up
Perceptual Assessment and Acoustic Voice Analysis as Screening Tests for Vocal Fold Paresis After Thyroid or Parathyroid Surgery.The aim of this study was to evaluate the reliability of clinician-based perceptual assessment of voice and computerized acoustic voice analysis as screening tests for vocal fold paresis or paralysis (VFP) after thyroid and parathyroid surgery.
Maria Heikkinen, Elina Penttilä, Mari Qvarnström, Kimmo Mäkinen, Heikki Löppönen, Jussi M Kärkkäinen
2747 related Products with: Perceptual Assessment and Acoustic Voice Analysis as Screening Tests for Vocal Fold Paresis After Thyroid or Parathyroid Surgery.1,000 tests96 Tests100 tests100 assays24 tests100tests100 tests 96 Tests 500 tests192 Tests n100tests100 tests
#33249488 2020/11/30 To Up
Systematic review of the published guidelines on Barrett's esophagus: should we stress the consensus or the differences?Multiple guidelines on Barrett's esophagus (BE) have being published in order to standardize and improve clinical practice. However, studies have shown poor adherence to them. Our aim was to synthetize, compare, and assess the quality of recommendations from recently published guidelines, stressing similarities and differences. We conducted a search in Pubmed and Scopus. When different guidelines from the same society were identified, the most recent one was considered. We used the GRADE system to assess the quality of evidence. We included 24 guidelines and position/consensus statements from the European Society of Gastrointestinal Endoscopy, British Society of Gastroenterology, American Society for Gastrointestinal Endoscopy, American Gastroenterological Association, American College of Gastroenterology, Australian guidelines, and Asia-Pacific consensus. All guidelines defend that BE should be diagnosed when there is an extension of columnar epithelium into the distal esophagus. However, there is still some controversy regarding length and histology criteria for BE diagnosis. All guidelines recommend expert pathologist review for dysplasia diagnosis. All guidelines recommend surveillance for non-dysplastic BE, and some recommend surveillance for indefinite dysplasia. While the majority of guidelines recommend ablation therapy for low-grade dysplasia without visible lesion, others recommend ablation therapy or endoscopic surveillance. However, controversy exists regarding surveillance intervals and biopsy protocols. All guidelines recommend endoscopic resection followed by ablation therapy for neoplastic visible lesion. Several guidelines use the GRADE system, but the majority of recommendations are based on low and moderate quality of evidence. Although there is considerable consensus among guidelines, there are some discrepancies resulting from low-quality evidence. The lack of high-quality evidence for the majority of recommendations highlights the importance of continued well-conducted research in this field.
Inês Marques de Sá, António Dias Pereira, Prateek Sharma, Mário Dinis-Ribeiro
1941 related Products with: Systematic review of the published guidelines on Barrett's esophagus: should we stress the consensus or the differences?1
#33249487 2020/11/29 To Up
Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of Glioblastoma.Glioblastomas (GBMs) are the most common primary brains tumors in adults with almost 100% recurrence rate. Patients with lateral ventricle proximal GBMs (LV-GBMs) exhibit worse survival compared to distal locations for reasons that remain unknown. One potential explanation is the proximity of these tumors to the cerebrospinal fluid (CSF) and its contained chemical cues that can regulate cellular migration and differentiation. We therefore investigated the role of CSF on GBM gene expression and the role of a CSF-induced gene, SERPINA3, in GBM malignancy in vitro and in vivo.
Montserrat Lara-Velazquez, Natanael Zarco, Anna Carrano, Jordan Phillipps, Emily S Norton, Paula Schiapparelli, Rawan Alkharboosh, Jordina Rincon-Torroella, Stephanie Jeanneret, Teresa Corona, Jose Segovia, Mark E Jentoft, Kaisorn L Chaichana, Yan W Asmann, Alfredo Quinones-Hinojosa, Hugo Guerrero-Cazares
2536 related Products with: Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of Glioblastoma.61mg500 ug200 10 Modulators96 wells (1 kit)100 ug2ug100 extractions3 inhibitors 100 G
#33249427 2020/11/28 To Up
FRMD6 has tumor suppressor functions in prostate cancer.Available tools for prostate cancer (PC) prognosis are suboptimal but may be improved by better knowledge about genes driving tumor aggressiveness. Here, we identified FRMD6 (FERM domain-containing protein 6) as an aberrantly hypermethylated and significantly downregulated gene in PC. Low FRMD6 expression was associated with postoperative biochemical recurrence in two large PC patient cohorts. In overexpression and CRISPR/Cas9 knockout experiments in PC cell lines, FRMD6 inhibited viability, proliferation, cell cycle progression, colony formation, 3D spheroid growth, and tumor xenograft growth in mice. Transcriptomic, proteomic, and phospho-proteomic profiling revealed enrichment of Hippo/YAP and c-MYC signaling upon FRMD6 knockout. Connectivity Map analysis and drug repurposing experiments identified pyroxamide as a new potential therapy for FRMD6 deficient PC cells. Finally, we established orthotropic Frmd6 and Pten, or Pten only (control) knockout in the ROSA26 mouse prostate. After 12 weeks, Frmd6/Pten double knockouts presented high-grade prostatic intraepithelial neoplasia (HG-PIN) and hyperproliferation, while Pten single-knockouts developed only regular PIN lesions and displayed lower proliferation. In conclusion, FRMD6 was identified as a novel tumor suppressor gene and prognostic biomarker candidate in PC.
Jakob Haldrup, Siri H Strand, Clara Cieza-Borrella, Magnus E Jakobsson, Maria Riedel, Maibritt Norgaard, Stine Hedensted, Frederik Dagnaes-Hansen, Benedicte Parm Ulhoi, Rosalind Eeles, Michael Borre, Jesper V Olsen, Martin Thomsen, Zsofia Kote-Jarai, Karina D Sorensen
#33249424 2020/11/28 To Up
Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.The association of Cyclosporine A (CsA) and mycophenolate mofetil (MMF) has increased in the setting of reduced intensity conditioning (RIC). Nevertheless, the use of CsA or CsA+MMF has not been reported in a large and uniform cohort. We analyzed 497 patients with acute myeloid leukemia in complete remission (CR) who underwent matched unrelated donor (MUD) hematopoietic stem cell transplantation (HSCT). All patients received a fludarabine busulfan RIC regimen and anti-thymocyte globulin (ATG) with either CsA alone or in combination with MMF. The cumulative incidence (CI) of grade II-IV acute GvHD was 27% (95% CI 21-33%) for CsA and 33% (95% CI 27-38%) for CsA+MMF (p = 0.25). The 2-year CI of chronic GvHD was 38% (95% CI 31-45%) and 33% (95% CI 28-39%) for the CsA and the CsA+MMF group, respectively (p = 0.26). On multivariate analysis, no statistically significant differences with respect to relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS), overall survival (OS), acute and chronic GvHD were found between the two groups, also when conducting a subgroup analysis in peripheral blood stem cells (PBSC) recipients. Our results support the importance of randomized trial to identify patients who could benefit from the addition of MMF in MUD HSCT.
Annalisa Paviglianiti, Myriam Labopin, Didier Blaise, Gerard Socié, Claude Eric Bulabois, Bruno Lioure, Patrice Ceballos, Igor Wolfgang Blau, Gaelle Guillerm, Johan Maertens, Patrice Chevallier, Anne Huynh, Pascal Turlure, Eric Deconinck, Edouard Forcade, Arnon Nagler, Mohamad Mohty
1092 related Products with: Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.50ul (1mg/ml)100 ul100 ul100 ul100 ul0.1ml (1mg/ml)
#33249419 2020/11/29 To Up
A 37-Year-Old Saudi Man with a Calcified Intraventricular Astrocytoma.BACKGROUND Pilocytic astrocytoma is a low-grade glioma that is common in children. Pilocytic astrocytoma is a slow-growing neoplasm that may calcify and occurs throughout the central nervous system, but it has a preference to be located infratentorial in children. CASE REPORT Herein, we report an unusual intraventricular location of pilocytic astrocytoma with extensive calcification in a 37-year-old Saudi man who mainly presented with a headache. Although pilocytic astrocytoma can arise throughout the central nervous system, it very rarely arises from the ventricles, especially the lateral ventricle. CONCLUSIONS The majority of intraventricular tumors arise within the third and fourth ventricles. The unusual intraventricular location and the unexpected age group are the main difficulties in diagnosing an adult with intraventricular pilocytic astrocytoma. Intraventricular pilocytic astrocytoma can be missed radiologically and misled pathologically; therefore, it should be considered within the differential diagnosis of intraventricular tumors. To the best of our knowledge, this is the first case to be reported in Saudi Arabia.
Maryam Abdullah Al Saleem, Noor Said Alsafwani, Tarek Mohammad ElSharkawy, Sari Saleh Al-Suhibani, Wisam Essawi96-well plate X 21 mg5 mg100 μg 100ul 100ul 5 G10 mg25 mg5 mg50 mg
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia